- Home
- INSM vs DOCU Comparison
INSM vs DOCU Comparison
Compare INSM & DOCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- DOCU
- Stock Information
- Founded
- INSM 1988
- DOCU 2003
- Country
- INSM United States
- DOCU United States
- Employees
- INSM N/A
- DOCU N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- DOCU EDP Services
- Sector
- INSM Health Care
- DOCU Technology
- Exchange
- INSM Nasdaq
- DOCU Nasdaq
- Market Cap
- INSM 17.3B
- DOCU 16.6B
- IPO Year
- INSM 2000
- DOCU 2018
- Fundamental
- Price
- INSM $102.68
- DOCU $75.13
- Analyst Decision
- INSM Strong Buy
- DOCU Hold
- Analyst Count
- INSM 17
- DOCU 15
- Target Price
- INSM $106.80
- DOCU $91.42
- AVG Volume (30 Days)
- INSM 4.1M
- DOCU 4.6M
- Earning Date
- INSM 08-07-2025
- DOCU 06-05-2025
- Dividend Yield
- INSM N/A
- DOCU N/A
- EPS Growth
- INSM N/A
- DOCU 922.41
- EPS
- INSM N/A
- DOCU 5.25
- Revenue
- INSM $381,030,000.00
- DOCU $3,030,753,000.00
- Revenue This Year
- INSM $28.03
- DOCU $8.27
- Revenue Next Year
- INSM $120.54
- DOCU $6.48
- P/E Ratio
- INSM N/A
- DOCU $14.20
- Revenue Growth
- INSM 20.77
- DOCU 7.85
- 52 Week Low
- INSM $60.40
- DOCU $48.80
- 52 Week High
- INSM $102.70
- DOCU $107.86
- Technical
- Relative Strength Index (RSI)
- INSM 78.76
- DOCU 38.27
- Support Level
- INSM $98.46
- DOCU $73.62
- Resistance Level
- INSM $102.00
- DOCU $76.34
- Average True Range (ATR)
- INSM 3.50
- DOCU 2.37
- MACD
- INSM 2.61
- DOCU -1.13
- Stochastic Oscillator
- INSM 99.61
- DOCU 7.17
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.